NASDAQ:NDRA ENDRA Life Sciences (NDRA) Stock Price, News & Analysis $8.10 +0.10 (+1.25%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$8.08 -0.02 (-0.25%) As of 07/11/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock About ENDRA Life Sciences Stock (NASDAQ:NDRA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ENDRA Life Sciences alerts:Sign Up Key Stats Today's Range$7.78▼$8.6250-Day Range$3.09▼$8.8452-Week Range$2.90▼$170.63Volume296,139 shsAverage Volume536,923 shsMarket Capitalization$5.99 millionP/E RatioN/ADividend YieldN/APrice Target$50.00Consensus RatingBuy Company Overview ENDRA Life Sciences Inc. (NASDAQ: NDRA) is a medical technology company focused on developing and commercializing advanced imaging solutions for clinical and preclinical applications. The company’s proprietary Thermo Acoustic Enhanced Ultrasound (TAEUS) platform uses patented nanoemulsion-based contrast agents to generate high-resolution thermal maps of tissue. By combining ultrasound with thermoacoustic technology, ENDRA’s systems aim to provide clinicians with quantitative insights into tissue composition, addressing unmet needs in monitoring liver health, cancer therapy response and other disease states. Founded in 2009 and headquartered in Ann Arbor, Michigan, ENDRA has evolved from a research-driven start-up into a publicly traded entity following a Nasdaq listing in late 2014. Since its inception, the firm has collaborated with leading academic institutions and secured regulatory designations to support its clinical development programs. The company’s Strata™ platform is designed for noninvasive, point-of-care imaging of liver steatosis, while additional preclinical systems target drug development workflows by enabling real-time assessment of tissue changes in oncology and cardiovascular research models. ENDRA serves a range of geographies, with its principal markets in the United States and ongoing initiatives to expand into Europe and Asia through partnerships and clinical studies. The company’s leadership team combines experience in medical device innovation, regulatory affairs and commercialization. Under the direction of CEO Samer Nassif and Chief Medical Officer Sainil Harle, ENDRA continues to advance its TAEUS technology through pivotal trials, seeking to address growing healthcare challenges related to liver disease prevalence and the need for more effective imaging modalities.AI Generated. May Contain Errors. Read More ENDRA Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreNDRA MarketRank™: ENDRA Life Sciences scored higher than 58% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingENDRA Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageENDRA Life Sciences has only been the subject of 1 research reports in the past 90 days.Read more about ENDRA Life Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ENDRA Life Sciences are expected to grow in the coming year, from ($47.46) to ($15.38) per share.Price to Book Value per Share RatioENDRA Life Sciences has a P/B Ratio of 1.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about ENDRA Life Sciences' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.10% of the float of ENDRA Life Sciences has been sold short.Short Interest Ratio / Days to CoverENDRA Life Sciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ENDRA Life Sciences has recently decreased by 6.51%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldENDRA Life Sciences does not currently pay a dividend.Dividend GrowthENDRA Life Sciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.10% of the float of ENDRA Life Sciences has been sold short.Short Interest Ratio / Days to CoverENDRA Life Sciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ENDRA Life Sciences has recently decreased by 6.51%, indicating that investor sentiment is improving significantly. News and Social Media2.7 / 5News Sentiment0.93 News SentimentENDRA Life Sciences has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for ENDRA Life Sciences this week, compared to 0 articles on an average week.Search Interest5 people have searched for NDRA on MarketBeat in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ENDRA Life Sciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.04% of the stock of ENDRA Life Sciences is held by insiders.Percentage Held by InstitutionsOnly 1.19% of the stock of ENDRA Life Sciences is held by institutions.Read more about ENDRA Life Sciences' insider trading history. Receive NDRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ENDRA Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address NDRA Stock News HeadlinesENDRA Life Sciences Inc News (NDRA) - Investing.comJuly 3, 2025 | investing.comENDRA Life Sciences Inc. (NDRA) - Yahoo FinanceJune 25, 2025 | finance.yahoo.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.July 13 at 2:00 AM | Brownstone Research (Ad)ENDRA’s Ongoing Multisite Pilot Study Reveals Important Enhancements to Boost TAEUS Liver Accuracy and Repeatability Against MRI Gold StandardJune 16, 2025 | finance.yahoo.comENDRA Life Sciences Provides a Business Update and Reports First Quarter 2025 Financial ResultsMay 15, 2025 | businesswire.comENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business UpdateMarch 31, 2025 | finance.yahoo.comENDRA Life Sciences Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emerging GLP-1 TherapiesMarch 31, 2025 | businesswire.comENDRA Life Sciences Inc Registered Shs NDRAFebruary 2, 2025 | morningstar.comMSee More Headlines NDRA Stock Analysis - Frequently Asked Questions How have NDRA shares performed this year? ENDRA Life Sciences' stock was trading at $6.26 at the beginning of 2025. Since then, NDRA shares have increased by 29.4% and is now trading at $8.10. How were ENDRA Life Sciences' earnings last quarter? ENDRA Life Sciences Inc. (NASDAQ:NDRA) posted its quarterly earnings results on Monday, March, 31st. The company reported ($9.40) EPS for the quarter, missing analysts' consensus estimates of ($4.10) by $5.30. When did ENDRA Life Sciences' stock split? Shares of ENDRA Life Sciences reverse split before market open on Tuesday, August 20th 2024.The 1-50 reverse split was announced on Friday, August 16th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 19th 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. When did ENDRA Life Sciences IPO? ENDRA Life Sciences (NDRA) raised $10 million in an initial public offering on Friday, February 3rd 2017. The company issued 2,000,000 shares at $5.00-$5.50 per share. Dougherty & Company and Dawson James Securities served as the underwriters for the IPO. How do I buy shares of ENDRA Life Sciences? Shares of NDRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ENDRA Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that ENDRA Life Sciences investors own include Bionano Genomics (BNGO), Cocrystal Pharma (COCP), AMC Entertainment (AMC), Plug Power (PLUG), Mustang Bio (MBIO), SNDL (SNDL) and BIOLASE (BIOL). Company Calendar Last Earnings3/31/2025Today7/13/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:NDRA CIK1681682 Webwww.endrainc.com Phone(734) 335-0468FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Price Target for ENDRA Life Sciences$50.00 High Price Target$50.00 Low Price Target$50.00 Potential Upside/Downside+517.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($172.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.51 million Net MarginsN/A Pretax MarginN/A Return on Equity-140.96% Return on Assets-106.14% Debt Debt-to-Equity RatioN/A Current Ratio3.85 Quick Ratio3.85 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.77 per share Price / Book1.70Miscellaneous Outstanding Shares740,000Free Float738,000Market Cap$5.99 million OptionableNot Optionable Beta-0.18 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:NDRA) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ENDRA Life Sciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ENDRA Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.